STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Zomedica Corp (NYSE American: ZOM) delivers innovative veterinary health solutions through advanced diagnostics and therapeutic technologies for companion animals and equines. This dedicated news hub provides investors and veterinary professionals with timely updates on corporate developments directly impacting animal healthcare innovation.

Access official press releases covering product launches, financial results, and strategic partnerships that shape Zomedica's position in veterinary medicine. Our curated collection ensures transparent access to regulatory filings, technology advancements, and market expansion initiatives without promotional bias.

Key updates on Zomedica's diagnostic platforms including TRUFORMA® assays, therapeutic device innovations, and clinical validation studies. Monitor operational milestones affecting veterinary practice efficiencies and animal health outcomes through verified corporate communications.

Bookmark this page for streamlined access to Zomedica's latest developments. Combine regular visits with professional financial advice when making investment or practice management decisions related to veterinary healthcare technologies.

Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) announced plans to expand its direct sales organization while phasing out distributor-based sales. This transition is prompted by anticipated changes affecting their current distributor's marketing effectiveness. CEO Robert Cohen stated that despite a potential slowdown in initial TRUFORMA® sales, this strategic move aims to fortify their market presence. Currently, Zomedica employs a team of 10 sales personnel. The company expresses confidence in its financial strength to support this transition and improve long-term sales capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) has announced its first veterinarian sale of TRUFORMA®, marking a significant step into commercialization. CEO Robert Cohen highlighted the team's dedication over the past two years to bring this innovative diagnostic tool to market ahead of schedule. The TRUFORMA® platform utilizes advanced Bulk Acoustic Wave technology and offers critical assays, including cortisol, TSH, and total T4, essential for managing adrenal and thyroid conditions in pets. The product aims to significantly improve veterinary diagnostics and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
none
-
News
Rhea-AI Summary

Zomedica Corp. (ZOM) has successfully exchanged all 12 outstanding Series 1 Preferred Shares for 24,719,101 common shares, eliminating a $108 million liquidation preference and a 9% royalty on net sales. This move is seen as a way to enhance shareholder value and clean the balance sheet ahead of the commercialization of its diagnostic platform, TRUFORMA®. Zomedica's field personnel and sales representatives have completed training in preparation for TRUFORMA's launch. The platform leverages patented Bulk Acoustic Wave technology, ensuring reliable point-of-care diagnostics for veterinarians.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) announced its financial results for the year ended December 31, 2020, reporting a net loss of approximately $16.9 million, or $0.05 per share, down from a loss of $19.8 million, or $0.19 per share in 2019. The company had no revenues in 2020, with R&D expenses decreasing by 22% to $8 million. General and administrative expenses also fell by 15% to $6 million. Zomedica's cash reserves improved significantly to $62 million from $0.5 million year-over-year, aided by substantial financing activities. As of February 26, 2021, cash stood at approximately $277.5 million after further equity offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.16%
Tags
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) announced the full exercise of an over-allotment option for a public offering, resulting in the purchase of an additional 13,697,368 common shares at $1.90 per share. This adds approximately $200 million to gross proceeds. The funds will support the development of Zomedica’s diagnostic platforms, strategic acquisitions, and potential repurchases of Series 1 Preferred Shares. H.C. Wainwright & Co. managed the offering, and securities are available under a previously filed Form S-3 registration statement. The offering excludes Canadian residents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.78%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) has successfully closed a public offering of 91,315,790 common shares priced at $1.90 each, generating gross proceeds of approximately $173.5 million. The company has granted underwriters an option to purchase up to 13,697,368 additional shares. Proceeds will be allocated to the development of diagnostic platforms, potential strategic acquisitions, and general corporate purposes, including possible repurchase of outstanding Preferred Shares. The offering was managed by H.C. Wainwright & Co. and was made under an effective shelf registration with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) has announced an increased public offering of 91,315,790 common shares, priced at $1.90 per share, due to high demand. The gross proceeds are expected to reach approximately $173.5 million, aimed at further developing diagnostic platforms and potential strategic acquisitions. The closing of the offering is anticipated around February 11, 2021. Additionally, the underwriter has a 30-day option to purchase up to 13,697,368 additional shares at the same price. This offering will not be available to residents of Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) announced an underwriting agreement with H.C. Wainwright & Co., LLC to purchase 13,157,895 common shares at $1.90 each, aiming for gross proceeds of approximately $25.0 million. Closing is expected around February 11, 2021, pending customary conditions. A 30-day option for an additional 1,973,684 shares is also granted. Proceeds will be used for the development of diagnostic platforms, milestone payments, potential acquisitions, and general corporate purposes, including a possible repurchase of Series 1 Preferred Shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.07%
Tags
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) announces a distribution agreement with Miller Veterinary Supply for its first product, TRUFORMA™, set to launch on March 30, 2021. Miller, a leading veterinary distributor with a century-long history, will cover states from Texas to Maine, enhancing customer service through Zomedica's sales support. TRUFORMA™ utilizes advanced Bulk Acoustic Wave technology for precise diagnostics at the point-of-care, backed by approximately 70 patents. Both companies emphasize commitment to quality and service in the veterinary market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) provided a shareholder update on key developments. CEO Robert Cohen expressed optimism for 2021, highlighting progress in product development and strategic initiatives. Zomedica focuses on innovative point-of-care diagnostic tools for veterinary use, aimed at enhancing pet healthcare. The company outlines its commitment to improving diagnostics for dogs and cats, creating potential for growth in the veterinary sector. Zomedica aims to bolster its market presence while addressing the challenges posed by the ongoing global pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

95.35M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR